Key result
PCOS is linked to ~19% lower serum PON1 activity and higher atherogenic lipid ratios.
Why the study?
Women with polycystic ovarian syndrome usually have dyslipidemia and an elevated cardiovascular risk, and paraoxonase-1 may contribute to changes in the apolipoprotein profile linked to atherogenesis. This study investigated the connection between the atherogenic apolipoprotein profile and serum PON1 activity in PCOS-affected women.
Case-Control (n=80)
No
Women with polycystic ovary syndrome exhibit significantly reduced antioxidant paraoxonase-1 activity alongside an elevated ApoB/ApoA-1 ratio, highlighting a link between impaired HDL antioxidant defense and an atherogenic lipid profile independent of BMI.
Answers are grounded in this paper and cite their sources.
Lower PON1 activity signals potential cardiometabolic vulnerability in PCOS; hypothesis-generating and requires prospective validation before clinical use.
Background Women with polycystic ovarian syndrome (PCOS) usually have dyslipidemia and an elevated cardiovascular risk. Paraoxonase-1 (PON1), an HDL-associated antioxidant enzyme, may contribute to changes in the apolipoprotein profile linked to atherogenesis. Aim of the Study: To investigate the connection between the atherogenic apolipoprotein profile and serum PON1 activity in PCOS-affected women. Methods: This case-control study included 50 women with newly diagnosed PCOS and 30 age-matched healthy controls. Apolipoprotein A-1 (ApoA-1), Apolipoprotein B (ApoB), serum PON1 activity, and the ApoB/ApoA-1 ratio were assessed. Independent samples t-test, Pearson's correlation analysis, and multiple linear regression analysis were performed. Results: While ApoB levels and the ApoB/ApoA-1 ratio were considerably greater than those of healthy controls, women with PCOS had significantly reduced PON1 activity and ApoA-1 concentrations (all P < 0.001). PON1 activity was significantly correlated negatively with BMI, ApoB, and the ApoB/ApoA-1 ratio, and positively with ApoA-1. After controlling for age and BMI, multiple linear regression analysis showed that PCOS was still independently linked to decreased PON1 activity. Study limitation: It is crucial to consider the several limitations of this study when assessing the findings. First, because of the single-center design and limited sample size, the results might not be as widely applicable. Second, a causal connection between decreased PON1 activity and the noted changes in the apolipoprotein profile cannot be established due to the case-control design. Third, no inflammatory biomarkers nor traditional lipid profile measures (total cholesterol, LDL-C, HDL-C, and triglycerides) were assessed. Finally, bigger prospective multicenter investigations are needed to corroborate these findings and further elucidate the significance of PON1 as a possible biomarker of cardiometabolic risk in women with PCOS. Conclusion: Reduced PON1 activity is linked to an unfavorable apolipoprotein profile in PCOS patients, suggesting that the development of atherogenic lipid abnormalities may be influenced by inadequate antioxidant defense.
No takes yet. Share an insight, caveat, or question.
Huda Falah Joodi (2026) conducted a case-control in Polycystic ovary syndrome (PCOS) (n=80). Polycystic ovary syndrome (PCOS) vs. Healthy age-matched women without PCOS was evaluated on Serum paraoxonase-1 (PON1) activity (mIU/mL) (B -15.67 (adjusted for age, BMI, and ApoB/ApoA-1 ratio), 95% CI -25.5 to -5.8, p=<0.001). Women with PCOS had lower serum PON1 activity and higher ApoB/ApoA-1 ratios than healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: